dc.creatorRodriguez, Cristian Ramon
dc.creatorAlvarez, Lautaro Damian
dc.creatorDansey, Maria Virginia
dc.creatorPaolo, Luciano Sebastián
dc.creatorVeleiro, Adriana Silvia
dc.creatorPecci, Adali
dc.creatorBurton, Gerardo
dc.date.accessioned2021-07-06T22:15:30Z
dc.date.accessioned2022-10-15T09:52:52Z
dc.date.available2021-07-06T22:15:30Z
dc.date.available2022-10-15T09:52:52Z
dc.date.created2021-07-06T22:15:30Z
dc.date.issued2017
dc.identifierFluorinated oxysterol analogues: Synthesis, molecular modelling and liver X receptor activity; 17th Tetrahedron Symposium: Challenges in Biological, Bioorganic, Organic & Medicinal Chemistry; Barcelona; España; 2016; 268-276
dc.identifier0960-0760
dc.identifierhttp://hdl.handle.net/11336/135600
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4372604
dc.description.abstractLiver X receptors (LXRs) are nuclear receptors that play central roles in the transcriptional control of lipid metabolism. They also modulate immune and inflammation responses in macrophagues and have multiple roles in cancer biology. The ability of LXRs to integrate metabolic and inflammation signaling makes them particularly attractive targets for intervention in human metabolic diseases. The undesirable effect of LXR agonists on hepatic lipogenesis has prompted the development of LXR antagonists and inverse agonists.2 Several cholestenoic acids are endogenous LXR ligands (e.g. 25R-cholestenoic acid (1)),3 recently we showed that compound 2, a 27-nor analogue of 1, is an inverse agonist and antagonist of LXRs. We have now prepared two fluorinated analogues 3 and 4 from the readily available aldehyde 5. The key step was a Reformatsky reaction with ethyl bromodifluoroacetate under high intensity ultrasound (HIU) irradiation, followed by a BartonMcCombie type deoxygenation to give difluoroester 6 (scheme). LXR activity was evaluated in a luciferase reporter assay in HEK293T cells co-transfected with full length human LXRa and LXRb. At 10 uM the difluoroacid 3 was an inverse agonist and antagonist, similar to its nonfluorinated analog 2, while the difluoroalcohol 4 was an agonist. To investigate the molecular basis of action of ligands 3 and 4, we performed molecular dynamics simulations in our model of LXR.4 The LXR-4 complex maintained a stable agonist conformation similar to that of LXR-GW3965 complex (synthetic agonist) with both fluorine atoms and the 26-hydroxyl alternating in the interaction with His-435. A major change was observed for the LXR-3 complex although different to that observed with inverse agonist 2: Helix-11 is destabilized changing the secondary structure in this region of LXR that carries part of the AF-2 domain (where coactivators and corepressors bind), but without affecting the position of helix-12
dc.languageeng
dc.publisherPergamon-Elsevier Science Ltd
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/abs/pii/S096007601630200X
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1016/j.jsbmb.2016.07.001
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.sourceLibro de resúmenes
dc.sourceThe Journal of Steroid Biochemistry and Molecular Biology
dc.subjectFLUOROSTEROLS
dc.subjectLIVER X RECEPTOR
dc.subjectLXR
dc.subjectCHOLESTENOIC ACID
dc.titleFluorinated oxysterol analogues: Synthesis, molecular modelling and liver X receptor activity
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.typeinfo:eu-repo/semantics/conferenceObject
dc.typeinfo:ar-repo/semantics/documento de conferencia


Este ítem pertenece a la siguiente institución